The effectiveness of tumor necrosis factor α antibody (infliximab) in treating recalcitrant psoriasis: A report of 2 cases

Archives of Dermatology

Volumn 138, Issue 5, 2002, Pages 644-648

  O'Quinn, Ryan P ^a   Miller, Jami L ^a  

^a VANDERBILT UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CALCIPOTRIOL; CYCLOSPORIN; CYTOKINE; DIPHENHYDRAMINE; ETRETIN; ETRETINATE; HYDROXYUREA; INFLIXIMAB; METHOTREXATE; PARACETAMOL; PSORALEN; RETINOID; STEROID; TAZAROTENE; TIOGUANINE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ADULT; ARTICLE; AUTOIMMUNE DISEASE; CASE REPORT; CROHN DISEASE; CYTOKINE PRODUCTION; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG INFUSION; DRUG TOLERABILITY; FEMALE; HUMAN; HUMAN TISSUE; KERATINOCYTE; MALE; PALLIATIVE THERAPY; PHENOTYPE; PRIORITY JOURNAL; PSORIASIS; RHEUMATOID ARTHRITIS; ULTRAVIOLET RADIATION;

ADULT; ANTIBODIES, MONOCLONAL; AUTOIMMUNE DISEASES; FEMALE; HUMANS; MALE; MIDDLE AGED; PSORIASIS; RECURRENCE; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0036578658     PISSN: 0003987X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Nuclear factor-κB: A pivotal transcription factor in chronic inflammatory diseases
2. Immune and inflammatory processes in cutaneous tissues: Mechanisms and speculations
3. A novel form of TNF/cachectin is a cell surface cytotoxic transmembrane protein: Ramifications for the complex physiology of TNF
4. The immunologic and genetic basis of psoriasis
5. The cytokine network in lesional and lesion-free psoriatic skin is characterized by a T-helper type 1 cell-mediated response
6. The majority of epidermal T cells in psoriasis vulgaris lesions can produce type 1 cytokines, interferon-γ, interleukin-2, and tumor necrosis factor-α, defining TC1 (cytotoxic T lymphocyte) and TH1 effector populations
7. Cellular localization of interleukin-8 and its inducer, tumor necrosis factor-α in psoriasis
8. Highly increased levels of tumor necrosis factor-α and other proinflammatory cytokines in psoriatic arthritis synovial fluid
9. Patterns of cytokine production in psoriatic synovium
10. An important role of tumor necrosis factor-α in the induction of adhesion molecules in psoriasis
11. Characterization of intercellular adhesion molecule-1 and HLA-DR expression in normal and inflamed skin: Modulation by recombinant γ interferon and tumor necrosis factor
12. Mast cells of psoriatic and atopic dermatitis skin are positive for TNF-α and their degranulation is associated with expression of ICAM-1 in the epidermis
13. Overexpression of extracellular matrix receptors (VLA-3, 5 and 6) on psoriatic keratinocytes
14. Increased serum soluble Fas, tumor necrosis factor-α, and interleukin 6 concentrations in generalized pustular psoriasis
15. Is sustained production of tumor necrosis factor-α relevant to the development of pustular psoriasis?
16. Tumor necrosis factor-α gene polymorphism in psoriasis
17. A TNF-α promoter polymorphism is associated with juvenile onset psoriasis and psoriatic arthritis
18. Etanercept in the treatment of psoriatic arthritis and psoriasis: A randomised trial
19. Construction and initial characterization of a mouse-human anti-TNF antibody
20. Chimeric anti-TNF-α monoclonal antibody cA2 binds recombinant transmembrane TNF-α and activates immune effector functions
21. Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2)
22. A short term study of chimeric monoclonal antibody (cA2) to tumor necrosis factor alpha for Crohn's disease
23. Summary of clinical trials in rheumatoid arthritis using infliximab, an anti-TNF-α treatment
24. Tumor necrosis factor-α antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn's ileocolitis
25. Decrease in cellularity and expression of adhesion molecules by anti-tumor necrosis factor-α monoclonal antibody treatment in patients with rheumatoid arthritis
26. Modulation of angiogenic vascular endothelial growth factor by tumor necrosis factor-α and interleukin-1 in rheumatoid arthritis
27. Randomised double-blind comparison of chimeric monoclonal antibodies to tumor necrosis factor-α
28. Infliximab (Remicade) for Crohn's disease
29. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor (α) monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis
30. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease
31. Disease activity and risk of lymphoma in patients with rheumatoid arthritis: Nested case-control study
32. Treatment with anti-tumor necrosis factor alpha (TNF-α) monoclonal antibody dramatically decreases the clinical activity of psoriasis lesions
33. Further evidence for an association between psoriasis, Crohn's disease, and ulcerative colitis